IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2/M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity.

IMS2186 (0.3-10 μM; 22 h) inhibits the proliferation of human fibroblasts and human cancer cells with IC50 values of 1.0-3.0 μM and 0.3-3.0 μM, respectively. IMS2186 (0-10 μM; 22 h) also inhibits endothelium formation with an IC50 of 0.1-0.3 μM under 10 ng/mL VEGF stimulation. Additionally, IMS2186 (0.1-10 μM; 24 h) inhibits the production of pro-inflammatory cytokines PGE2/TNF-a in macrophages with an IC50 of 0.3-1 μM, and it inhibits macrophage migration with an IC50 of 1 μM within 1.5 hours[1].

IMS2186 (2.5 mg in 0.5 mL; vitreous injection; single dose) was administered to rabbit eyes with no ocular toxicity, and IMS2186 (100 μg/eye, i.e. 50 μg/μL solution dosage 2.0 μL; single dose) exhibited an anti-proliferative effect on the rat model of laser-induced choroidal neovascularization (CNV) [1].